The lack of effects of the immunotherapy targeting the PDL1/PD1 axis on T cell‐mediated immunity has been attributed to low tumor mutation burden and low neoantigens (Anagnostou et al., 2017; Rizvi et al., 2015). Here, CD274 is linked to neoplasm.